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Appearance of two isomers of inositol trisphosphate (InsP,) was observed when PH]inositol prelabelled rat 
heart ventricles were stimulated for 10 and 30 s with noradrenaline. In contrast, inositol tetrakisphosphate 
(InsP,) could not be detected. However the existence of the inositol tris/tetrakisphosphate pathway was 
demonstrated by studying PI-Qnositol l,rl,Qrisphosphate (Ins-1,4,5-P,) metabolism in a soluble fraction 
of rat heart. There, PHIIns-1,4,5-P, was phosphorylated to form PHIIns-1,3,4,5-P,. Raising [Cazf] from 
1 nM to 1 PM increased InsP, kinase activity by 2-fold (EC,, for Ca2+ approx. 56 nM). This effect appeared 
to be due to an increase of the apparent V,,, of the enzyme while the apparent K,,, was unchanged. 
Inositol trisphosphate; Inositol tetrakisphosphate; Ca2+; (Rat heart) 
1. INTRODUCTION 
In skeletal and cardiac muscles, polyphos- 
phoinositide hydrolysis by phospholipase C is in- 
creased by electrical or hormonal stimulation, thus 
producing inositol 1,4,5_trisphosphate (Ins-1,4,5- 
P3) and diacylglycerol [I ,2]. Ins-l ,4,5-P3 was 
shown to release Ca2+ from sarcoplasmic reti- 
culum and promote tension in skinned fibers 
([3-51 but see also [6-g]). Diglycerides activate 
protein kinase C which in turn may influence cer- 
tain ionic permeabilities [9-111 and the sensitivity 
of myofilaments to Ca2+ [12]. 
phosphate (InsPA) which is then dephosphorylated 
to give inositol 1,3,4_trisphosphate. It has been 
already shown that this second isomer of InsP3’as 
well as Ins-1,4,5-P3 can release Ca2+ from per- 
meabilized Swiss 3T3 cells [20] and that InsP4 may 
play a key role in sea urchin egg activation by 
stimulating Ca2+ fluxes through the cell plasma 
membrane [21]. It is thus of interest to study fur- 
ther the inositol tris/tetrakisphosphate pathway in 
the heart. 
Besides its rapid hydrolysis to inositol 
1,4-bisphosphate (InsPz) by a phosphomonoester- 
ase, another pathway for Ins-1,4,5-P3 metabolism 
has recently been described in several tissues 
[ 13-191. It consists of the phosphorylation of 
Ins-l ,4,5-P3 by a kinase to inositol 1,3,4,5-tetrakis- 
In this work, we have examined the formation of 
the two InsP3 isomers following an a*l-adrenergic 
stimulation of rat heart. In addition, we have 
demonstrated the presence of an InsP3 kinase 
which is stimulated by Ca2+ in the soluble fraction 
of these cells. 
2. MATERIALS AND METHODS 
2.1. Materials 
Correspondence address: D. Renard, Unite de Recher- Collagenase was purchased from Boehringer; 
ches de Physiologie et Pharmacologic Cellulaire, noradrenaline, propranolol, atropine and 2,3- 
INSERM U-274, UniversitC Paris-Sud (Bat. 443), bisphosphoglycerate were from Sigma. myo- 
F-91405 Orsay Cedex, France [2-3H]Inositol (619 GBq/mmol) was obtained 
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from New England Nuclear; sodium [32Plphos- 
phate from CEA (France); D-myo-inositol 1,4,5- 
triphosphate, D-myo-[2-3H]inositol 1,4,5-triphos- 
phate and L-myo-[U-‘4C]inositol-L-phosphate 
were purchased from Amersham (France). All 
other chemicals were of reagent grade. 
2.2. Tissue incubation and labelling 
Isolated right ventricles from female Wistar rats 
(160-180 g) were labelled with [3H]myo-inositol 
(1.11 MBq/ml) for 3 h in a modified Krebs solu- 
tion containing: 116 mM NaCl, 5.4 mM KCl, 
0.9 mM CaC12, 0.81 mM MgC12, 0.92 mM 
NaH2P04, 25 mM NaHC03 supplemented with 
glucose (1 g/l) and mannitol (0.4 g/l) under an at- 
mosphere of O&O2 (19 : 1) as described [2]. They 
were rinsed, preincubated in Krebs solution con- 
taining 10 mM LiCl, 10 FM propranolol and 
10pM atropine and then stimulated or not with 
50 PM noradrenaline for 10 or 30 s. The incuba- 
tion was stopped by freeze clamping and [3H]- 
inositol phosphates were extracted using HC104 as 
in [2]. Isolated hepatocytes from female Wistar 
rats (200-220 g) were prepared as described in 
[22]. They were labelled by incubating for 90 min 
in Eagle’s medium containing: 116 mM NaCl, 
5.4 mM KCl, 1.8 mM CaC12, 0.81 mM MgClz, 
0.92 mM NaH2P04, 25 mM NaHCOs, 1 g of 
glucose/l, amino acids and vitamins supplemented 
with 1.5% gelatin and 1.11 MBq/ml of [3H]myo- 
inositol, under an atmosphere of Oz/CO2 (19 : 1) as 
in [23]. Cells were then washed and resuspended at 
8 x lo6 cells/ml in inositol free Eagle’s medium 
containing 10 mM LiCl. 450 fil samples of this cell 
suspension were incubated with 50 nM vasopressin 
or vehicle for 5 or 30 s. The reaction was ter- 
minated by addition of 200~1 of ice-cold 10% 
(v/v) HC104. 
2.3. Separation of [3H]inositol phosphates 
Neutralized samples of perchloric acid soluble 
material were analyzed by high pressure liquid 
chromatography (HPLC) on Partisyl SAX 10 col- 
umn following a modification [15] of the method 
described in [24]. After sample injection, the col- 
umn was washed for 3 min with Hz0 and the 
[3H]inositol polyphosphates subsequently eluted 
by three successive convex gradients (Waters 4, 2 
and 1 respectively) of increasing ammonium for- 
mate buffer (O-l .7 M) adjusted to pH 3.7 with or- 
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thophosphoric acid. The flow rate was 1.2 ml/min 
and the eluant was collected in 1 min fractions 
over the first 20 min and 0.2 min fractions over the 
next 15 min. [32P]Ins-1,4-P2 and [32P]Ins-1,4,5-P3 
were prepared from red blood cell ghosts activated 
by Ca2+ [25]. [2-3H]Ins-l,3,4,5-P4 was made from 
[2-3H]Ins-1,4,5-P3 using a soluble fraction of rat 
liver [ 141. Both labelled standards were purified by 
anion-exchange chromatography on a Dowex 1 x 
8 column (formate form) as in [26], diluted 5 times 
with water and desalted by lyophilization. 
2.4. Enzyme assay 
Both whole ventricles from one rat heart were 
homogenized in 2 ml of an ice-cold buffer contain- 
ing 250 mM sucrose, 5 mM Hepes, pH 7.5, and 
centrifuged for 90 min at 4°C (100000 x g). The 
resultant supernatant was designated as the soluble 
fraction. The buffer used to test enzyme activity 
contained 250 mM sucrose, 10 mM ATP, 20 mM 
MgC12, 50 mM Hepes, pH 7.3, 5 mM Na 
pyrophosphate, 2.5 mM Na 2,3-bisphosphoglycer- 
ate, 0.5 mM EGTA, 0.2 mg/ml saponin, Ins- 
1,4,5-P3 (0.5-5 PM) and [2-3H]Ins-1,4,5-P3 (8.14 
kBq/ml) or [32P]Ins-1,4,5-P3 (10000 dpm/ml). 
CaC12 was added to give free Ca2+ concentrations 
in the range of 1 nM to 100 PM, calculated by 
using a dissociation constant for the Ca-EGTA 
complex of 12.5 nM [27]. Enzyme assays were per- 
formed at 35°C with 50 pl of soluble fraction in a 
total volume of 500 pl. Incubations were started by 
addition of Ins-1,4,5-P3 and stopped with 33 ~1 of 
ice-cold 50% (v/v) HC104. 3H-labelled products 
were analyzed as explained above. Reaction rate 
was linear for 10 min. The kinase activity was 
calculated as follows: cpm of InsP41spec. act. of 
[3H]Ins-1,4,5-P3 x time of incubation. 
3. RESULTS AND DISCUSSION 
3. I. Presence of more than one InsP3 isomer in 
heart cells 
Experiments were performed to determine 
whether or not the InsP3 produced by hormone 
stimulation in rat heart contained the two different 
isomeric forms (Ins-l ,4,5-P3 and Ins-l ,3,4-P3) as 
already observed in other tissues [28-301. 3H- 
labelled isolated right ventricles were stimulated 
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for periods of either 10 or 30 s with a maximal 
dose of noradrenaline (50 ,uM). Because in isolated 
rat hepatocytes, the presence of the two InsP3 
isomers following hormonal stimulation is well 
established [28], experiments were run in parallel 
on isolated hepatocytes (labelled with [3H]inositol) 
stimulated 5 or 30 s with 50 nM vasopressin. 
Fig.1 shows the ‘H-labelled products eluted 
from heart (A) and liver extracts (B). In the 
absence of stimulation 4 peaks could be observed 
in both tissues. They were characterized by coelu- 
tion with appropriate standards: inositol 
monophosphate (Ins-l-P), hS-1,4-P2 and 
Ins-1,4,5-P3. The two InsP3 isomers were indeed 
identified according to a previous report 1241, 
Ins-l ,3,4-P3 was eluted with or very close to ATP, 
min 
10 15 20 2-5 
min 
and Ins-1,4,5-P3 was eluted shortly afterwards. 
In stimulated cells, the 3H-labelled peak corre- 
sponding to Ins-l ,4,5-P3 (24.8 min) predominated 
at the shorter time of stimulation (5 and 10 s for 
liver and heart, respectively). The other isomer 
(Ins-1,3,4-P3, 22.6 min) was much increased 
following longer stimulation period (30 s) whereas 
the peak at 24.8 min was unaffected. Moreover, in 
liver cells, a smaller peak corresponding to 
material more polar than Ins-1,4,5-P3 could be 
detected. It eluted at 1.7 M ammonium formate 
(30.4 min retention time) suggesting that it cor- 
responds to the peak identified as Ins-1,3,4,5-P4 in 
[29]. This figure also shows that in heart InsP3 
isomers did not accumulate as much as in liver; 
correlatively increases in InsP2 and InsP appeared 
@ 
IlISP 
~ 
10 
Ins-1.4-Pz 
Ins-1.4.5-q 
15 20 25 30 
min 
Fig. 1. Elution profile of inositol phosphates by HPLC. For experimental details see section 2. (A) The samples analyzed 
were neutralized perchloric acid extracts of right ventricles (100 mg wet wt) prelabelled with [3H]myo-inositol and 
stimulated or not (0) with 50,~M noradrenaline for 10 (0) or 30 s (A). Note the change in scale for InsP3. (B) The 
samples analyzed were neutralized perchloric acid extracts of hepatocytes (2.2 mg of cell protein) prelabelled with 
[‘H]myo-inositol and stimulated or not (a) with 50 nM vasopressin for 5 (0) or 30 s (A). Note the change of scale for 
InsP3 and InsP4. Identification of inositol phosphates is based on comparison with the elution profiles of [‘4C]Ins-P, 
[32P]Ins-1,4-Pz, [32P]Ins-1,4,5-P3 and [3H]Ins-1,4,5-P3. 
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very soon suggesting the presence of an efficient 
phosphomonoesterase in heart. 
Although InsP4 could not be detected in heart 
cells in vivo, the presence of Ins-1,3,4-PJ which has 
been repeatedly shown to result from InsP4 
dephosphorylation in other tissues [16-191 led us 
to investigate the presence of an Ins-1,4,5-P3 
kinase in the soluble fraction of heart. 
3.2. Detection of inositol tetrakisphosphate in the 
soluble fraction of heart cells 
To further examine the possibility that InsP4 was 
being produced in rat heart, we used subcellular 
fractions. Fig.2 shows a time course analysis of the 
metabolism of [3H]Ins-1,4,5-P3 (16,~M) in the 
presence of ATP, in the soluble fraction. The data 
show that, 1 min after the addition of 
2000 
E 
0 
1000 
I Ins-1,4,5-P3 
1 
QB 
8 
h-1,3,4- 
, 
0 
10 
[3H]Ins-l,4,5-P3 to the 100000 x g supernatant, a 
new more polar inositol-containing peak appeared, 
which was identified as InsP4 by coelution with 
[3H]InsP4 prepared from hepatocytes. InsP4 was 
not formed when ATP was absent. Simultaneously 
with the formation of InsP4, a shoulder arose on 
the Ins-l ,4,5-P3 peak. This coeluted with ATP and 
represented Ins-1,3,4-P3 (see above). InsP4 ac- 
cumulated and the ratio of the two InsP3 isomers 
was inversed with increased length of incubation. 
Fig.2 shows that InsP2 and InsP were formed too. 
Only one peak of InsP2 was observed which 
coeluted with a standard of [32P]Ins-1,4-P2 
prepared from 32P-labelled red cell ghosts ac- 
tivated by Ca2+ (see section 2). This suggests that 
InsP2 formation results from the attack of 
Ins-1,4,5-P3 by a phosphomonoesterase r moving 
Ins-1,3.4-P3 
h-1,4-q 
il r: 
L Ins-1,3.%,5-q 
30 
Time(min) 
0 
Ills- 
Ins-1,4-P* 
f 
Ins-l-P 
AL 
T---- 
10 
Ins-1$,5-Pa 
\ 
h-1,3,4,5-q 
A 
Fig.2. Time course of [3H]Ins-l,4,5-Ps conversion to [3H]InsP4. An aliquot of the soluble fraction (450,ug of protein 
in 50 ~1) was added to 500 pl of an incubation buffer containing 250 mM sucrose, 10 mM ATP, 20 mM MgC12,50 mM 
Hepes, pH 7.3, 5 mM Na pyrophosphate, 2.5 mM Na 2,3-bisphosphoglycerate, 0.5 mM EGTA, 0.2 mg/ml saponin, 
16 FM Ins-l ,4,5-P3 and [3H]Ins-l ,4,5-P3 (8.14 kBq/ml). CaC12 was added to give a free Ca’+ concentration of 10 pM. 
Incubations were performed at 35°C and were stopped after 1 min (A), 3 min (B) or 5 min (C) by addition of 50~1 
of 50% HC104. Similar results were obtained in 3 separate experiments. 
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PO:- from position 5. In agreement with the above 
results, InsP3 phosphomonoesterase has been 
reported to be soluble in platelets too, but partly 
soluble in hepatocytes and in the particulate frac- 
tion in other tissues [31-341. This phospho- 
monoesterase may hydrolyze Ins-l ,4,5-PS and 
Ins-1,3,4,5-Pd. Its activity might explain why we 
have been unable to detect InsP4 in vivo, since as 
shown above, as soon as it is formed InsP4 is 
dephosphorylated to Ins-1,3,4-P3. The addition of 
phosphomonoesterase inhibitors under in vitro 
conditions reduced InsP4 turnover and allowed it 
to accumulate. 
3.3. ~od~~at~o~ f InsP4 kinase activity by Cd?’ 
Cytosolic free Ca2+ varies 2-300 times/mm in 
rat heart cells. [Ca2+]i s also dependent on hor- 
monal stimulation [35,36]. In that respect, the 
possible dependence of Ins-1,4,5-P3 kinase activity 
upon Ca*+ is of physiological relevance. Ex- 
periments were further performed to test this 
possibility. 
As shown before the experiments were com- 
plicated by the presence of soluble enzyme(s) 
which dephosphorylates Ins-l ,4,5-P3 [25,3 1,32,37] 
and Ins-l ,3,4,5-P4 [29,37}. We have tentatively 
eliminated the phosphomonoesterase effects by in- 
cluding 2.5 mM bisphosphoglycerate in incubating 
solutions [25,37]. Under the conditions used (see 
section 2), the reaction rate was linear at least over 
a 10 min period (fig,-?), inset). The kinase activity 
was doubled by raising the free Ca2+ concentration 
from I nM to 1 pM (EC50 for Ca2’, approx. 
56 nM, fig.3). This effect was due to an increase in 
the apparent V,,, of the enzyme from 135.1 f 25.4 
to 253.5 f 26.5 pmol of InsP4 formed/min per mg 
of protein (n = 3, P < 0.05) in the presence of 
1 nM or 1 pM Ca2”, respectively (fig.4). It has 
been reported that, in RINmSF cells, Ins-1,4,5-P3 
kinase was stimulated by Ca*+ over the 
physiological concentration range [ 191 while in 
brain no relevant changes in kinase activity have 
been observed over the physiological concentration 
range [14]. The Ca2+ concentration required for 
half-maximal kinase activity is high when com- 
pared to the internal Ca2+ concentration reported 
in vivo [35,36]. If the enzyme has a physiological 
relevance, one has to assume that regulatory fac- 
tors have been lost during cell disruption. The 
apparent half-maximal substrate concentration 
9 8 7 8 5 4 -~OgkS*')M 
2+ 
~07~~~ 0.991m 1.20 Ca 
EGTA 
Fig.3. Ca2+-dependence of Ins-l,B,S-P3 kinase activity in 
a soluble fraction from rat heart. The protocol was 
identical to that described in the legend to fig.2. Final 
free Ca2+ concentrations are those plotted on the 
abscissa. The incubations lasted 10 min. Results are 
from one typical experiment out of 3. They are expressed 
as percentage of the maximal response obtained in the 
presence of 10 pM Ca” (118 pmol of InsP4 formed/min 
per mg of protein). 
E” 0.05 0 WE- 0 
*_ 
E 
0.04 
- 
Z 0.03 
E 0. 0.02 0 
z> 0.01 ‘,:.--- 0 I x’_ 
I I 1 , 
020.4 1 2 
l(PW 
S 
Fig.4 Ins-1,4,5-P3 kinase activity as a function of 
substrate concentration. The protocol was identical to 
that described in the legend to fig.2 except that 
Ins-l ,4,5-P3 was present at various concentrations 
(0.5-5 pM). Incubations lasted 3 min and the final free 
Ca2+ concentration was either 1 nM (0) or 1 pM (0). 
Results are from one typical experiment out of 3. 
121 
Volume 217, number 1 FEBS LETTERS June 1987 
5.61 + 1.59pM (n = 3, 1 nM Ca2+) and 5.58 + 
0.19 ,uM (n = 3, 1 PM Ca’+) was unchanged by 
Ca2+. The apparent Km of the kinase for 
Ins-1,4,5-P3 reported here is in keeping with 
Ins-1,4,5-P3 concentrations, determined chemical- 
ly or by biological assay, in activated cells [36,37]. 
Effective Ins-1,4,5-P3 concentrations required for 
Ca2+ release from sarcoplasmic reticulum are also 
in the ten micromolar range [3-51. 
The present study provides the first evidence 
that Ins-1,3,4-P3 is produced together with 
Ins-1,4,5-P3 in hormone-stimulated heart as 
reported for other cell types [28-301. It has been 
shown that the interconversion of the two InsP3 
isomers depends on the formation of a higher 
phosphorylated intermediate InsPd. InsP4 is syn- 
thesized from Ins-1,4,5-P3 in the presence of ATP 
by a kinase as reported in GH4 cells, brain, liver, 
adrenal glomerulosa cells and RINmSF cells 
[13-15,17,19]. The kinase appears to be Ca2+ sen- 
sitive. This alternative pathway may lead to inac- 
tivation of the well characterized messenger 
Ins-l ,4,5-P3 and the formation of another putative 
messenger, InsP4 [40,41]. 
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